Hongmei Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hongmei Yin has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Chaomang Zhu
Department of Radiotherapy, First Affiliated Hospital of Bengbu Medical College, Bengbu, China
1 shared publication- Duojie Li
Department of Radiotherapy, First Affiliated Hospital of Bengbu Medical College, Bengbu, China
1 shared publication - Jia Chen
Department of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
1 shared publication Mingxi Wang
Department of Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, China
1 shared publicationNannan Wei
Department of Radiotherapy, First Affiliated Hospital of Bengbu Medical College, Bengbu, China
1 shared publicationQiong He
Pathology Department Fudan University Shanghai Cancer Center Shanghai China
1 shared publication
Latest Publications
- Open Access
- 13 November 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 35 (12) , e24085
Drug metabolism‐related eight‐gene signature can predict the prognosis of gastric adenocarcinoma
Background: Metabolic abnormalities in patients with gastric adenocarcinoma lead to drug resistance and poor prognosis. Therefore, this study aimed to explore biomarkers that can predict the prognostic risk of gastric adenocarcinoma by analyzing drug metabolism‐related genes.Methods: The RNA‐seq and clinical information on gastric adenocarcinoma were downloaded from the UCSC and gene expression omnibus databases. Univariate and least absolute shrinkage and selection operator regression analyses were used to identify the prognostic gene signature of gastric adenocarcinoma. The relationships between gastric adenocarcinoma prognostic risk and tumor microenvironment were assessed using CIBERSORT, EPIC, QUANTISEQ, MCPCounter, xCell, and TIMER algorithms. The potential drugs that could target the gene signatures were predicted in WebGestalt, and molecular docking analysis verified their binding stabilities.Results: Combined with clinical information, an eight‐gene signature, includingGPX3,ABCA1,NNMT,NOS3,SLCO4A1,ADH4,DHRS7, andTAP1, was identified from the drug metabolism‐related gene set. Based on their expressions, risk scores were calculated, and patients were divided into high‐ and low‐risk groups, which had significant differences in survival status and immune infiltrations. Risk group was also identified as an independent prognostic factor of gastric adenocarcinoma, and the established prognostic and nomogram models exhibited excellent capacities for predicting prognosis. Finally, miconazole and niacin were predicted as potential therapeutic drugs for gastric adenocarcinoma that bond stably withNOS3andNNMTthrough hydrogen interactions.Conclusions: This study proposed a drug metabolism‐related eight‐gene signature as a potential biomarker to predict the gastric adenocarcinoma prognosis risks.
- 13 November 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 35 (12) , e24085
Open AccessDrug metabolism‐related eight‐gene signature can predict the prognosis of gastric adenocarcinoma
Background: Metabolic abnormalities in patients with gastric adenocarcinoma lead to drug resistance and poor prognosis. Therefore, this study aimed to explore biomarkers that can predict the prognostic risk of gastric adenocarcinoma by analyzing drug metabolism‐related genes.Methods: The RNA‐seq and clinical information on gastric adenocarcinoma were downloaded from the UCSC and gene expression omnibus databases. Univariate and least absolute shrinkage and selection operator regression analyses were used to identify the prognostic gene signature of gastric adenocarcinoma. The relationships between gastric adenocarcinoma prognostic risk and tumor microenvironment were assessed using CIBERSORT, EPIC, QUANTISEQ, MCPCounter, xCell, and TIMER algorithms. The potential drugs that could target the gene signatures were predicted in WebGestalt, and molecular docking analysis verified their binding stabilities.Results: Combined with clinical information, an eight‐gene signature, includingGPX3,ABCA1,NNMT,NOS3,SLCO4A1,ADH4,DHRS7, andTAP1, was identified from the drug metabolism‐related gene set. Based on their expressions, risk scores were calculated, and patients were divided into high‐ and low‐risk groups, which had significant differences in survival status and immune infiltrations. Risk group was also identified as an independent prognostic factor of gastric adenocarcinoma, and the established prognostic and nomogram models exhibited excellent capacities for predicting prognosis. Finally, miconazole and niacin were predicted as potential therapeutic drugs for gastric adenocarcinoma that bond stably withNOS3andNNMTthrough hydrogen interactions.Conclusions: This study proposed a drug metabolism‐related eight‐gene signature as a potential biomarker to predict the gastric adenocarcinoma prognosis risks.
- Open Access
- 1 August 2018
- Published by Wiley in Thoracic Cancer
- Vol. 9 (10) , 1215-1219
Factors relevant to the prognosis of patients with esophageal cancer who received intensity‐modulated radiotherapy
Background: The aim of this study was to evaluate the clinical factors relevant to the prognosis of patients with esophageal cancer who received intensity‐modulated radiotherapy (IMRT).Methods: The data of 60 patients admitted to our hospital from January 2014 to December 2015 with pathologically confirmed esophageal cancer were retrospectively reviewed. All patients received IMRT. Patients were divided into groups according to two‐year survival: those who survived > 2 years after treatment, and those who died within 2 years of treatment. The potential clinical factors relevant to prognosis were evaluated by logistic regression analysis.Results: Single factor analysis showed that lesion length (P < 0.05), tumor diameter (P < 0.05), T stage (P < 0.05), N stage (P < 0.05), and combined chemotherapy (P < 0.05) were associated with the prognosis of esophageal cancer patients who received IMRT. Logistic regression analysis demonstrated that T stage (odds ratio = 3.62; P < 0.05) and N stage (odds ratio = 2.98; P < 0.05) were independent factors relevant to prognosis.Conclusion: T stage and N stage influence the long‐term curative effects of IMRT for esophageal cancer. The higher the stage, the lower the two‐year survival rate.
- 1 August 2018
- Published by Wiley in Thoracic Cancer
- Vol. 9 (10) , 1215-1219
Open AccessFactors relevant to the prognosis of patients with esophageal cancer who received intensity‐modulated radiotherapy
Background: The aim of this study was to evaluate the clinical factors relevant to the prognosis of patients with esophageal cancer who received intensity‐modulated radiotherapy (IMRT).Methods: The data of 60 patients admitted to our hospital from January 2014 to December 2015 with pathologically confirmed esophageal cancer were retrospectively reviewed. All patients received IMRT. Patients were divided into groups according to two‐year survival: those who survived > 2 years after treatment, and those who died within 2 years of treatment. The potential clinical factors relevant to prognosis were evaluated by logistic regression analysis.Results: Single factor analysis showed that lesion length (P < 0.05), tumor diameter (P < 0.05), T stage (P < 0.05), N stage (P < 0.05), and combined chemotherapy (P < 0.05) were associated with the prognosis of esophageal cancer patients who received IMRT. Logistic regression analysis demonstrated that T stage (odds ratio = 3.62; P < 0.05) and N stage (odds ratio = 2.98; P < 0.05) were independent factors relevant to prognosis.Conclusion: T stage and N stage influence the long‐term curative effects of IMRT for esophageal cancer. The higher the stage, the lower the two‐year survival rate.